ABSTRACT
Background: Coronavirus disease (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus-2. Most of the people infected with the virus will have moderate respiratory illness and they recover without requiring special treatment. Aim: The aim of this study was to evaluate the role of ACE2 as a biomarker in patients with COVID-19 severe infection. Materials and methods: A case-control retrospective study included 90. subjects who were divided as the following : 60 COVID-19 patients who aged between 13-90 years with a positive real time -polymerase chain reaction (RT-PCR) for COVID-19,under monitoring the specialist doctor in terms of giving treatment and observing the clinical condition of the patient, patients with COVID-19 were divided in to 20 patients with severe symptoms who were admitted into the intensive care unit in the hospital, 20 patients with moderate symptoms who were admitted to the hospital ,and 20 patients with mild symptoms who were treated as an out patients. 30 individuals who were apparently healthy as a control group. Blood blood sample were collected from each patients fir determination of Serum Angiotensin Converting Enzyme 2 (ACE2) and LDH by ELISA. Results: The highest proportion of study group were aged ≥ 60years (55% and 40% respectively). According to gender the highest proportion of the study group were female s(51 % and 56.7% respectively), regarding the smoking status 28.3% of patient group and 50 % of control were current smokers, while the highest proportion of the patient group complained from severe COVID-19 infection . A significant difference p<0.05 in ACE2 levels between patient and control group so significant increase was observed in the level of the biomarkers (ACE2, LDH, ) with means (261.47pg/ml,495.28 iu/l, when measured in COVID-19 patients, in comparison with control group means ( 50.07 pg/ml, 288.16 iu/l,) respectively, which meaning that a positive correlations between ACE2 level and LDH ,Ferritin Conclusions: Present study revealed that ACE2 has a vital role in COVID-19 patients and in severity of systemic inflammation, , LDH, play an essential role in severity of COVID-19. © 2022, HIV Nursing. All rights reserved.
ABSTRACT
Hyper inflammation is found in severely ill COVID-19 sufferers;corresponding biomarkers may be helpful for risk classification. Our goal was to look at examine the correlation between COVID-19 severity and several biomarkers, such as serum ferritin, D-dimer and C-reactive protein (CRP), procalcitonin (PCT). This study aimed to evaluate the value of the LDH, Ferritin, D-dimer, CRP, Na+, and K+ as biomarkers in COVID-19 patients. In Tikrit general hospital's isolation unit and Kirkuk general hospital's isolation unit, patients with coronavirus were the subjects of a case-control study from the beginning of January through the end of March 2022. Ninety participants in the study made up the following groups: 30 people who appear to be in good health yet have poor real: 60 COVID-19 patients aged between 13 and 90 years with positive real-time polymerase with moderate symptoms who were admitted to hospital and 20 patients with mild symptoms who were treated as outpatients. Blood samples are taken to measure the levels of these biomarkers LDH, ferritin, D-dimer, CRP, Na+, and K+, in COVID-19 patients, and compared with the control group, a significant rise in the levels of the biomarkers (LDH, ferritin, CRP, and D-dimer) was seen with means of (261.4 pg/ml, 495.2 iu/l, 394.6 ng/mL, 82.34 mg/l and 165 and there were significant positive associations between ACE2 level and all of these markers, in comparison with control group means (50.07 pg/mL, 288.16 iu/l, 62.6 ng/ml,4.02 mg/l,188.93 ng/mL) respectively. The severity of COVID-19 is highly influenced by LDH, D-dimer, CRP, and ferritin. So, these biomarkers play an essential role in the severity of COVID- 19. © 2023 by SPC (Sami Publishing Company)